Cambridge, UK and Brussels, Belgium 16 December 2021:
Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, and Bioqube Ventures (“Bioqube”), a specialist European life sciences investment firm, announced today that they have entered into a collaboration, backed by Bioqube Factory Fund I, to incubate a drug discovery research project targeting autoimmune diseases.
AMSBIO has expanded its range of custom gene editing services to complement its extensive portfolio of off-the-shelf CRISPR/Cas9 products.
Cambridge UK: 15 December 2021
The PCML Group has become a Partner to join forces with One Nucleus. The One Nucleus Partner Programme is tailor-made to meet the needs of the Partner and One Nucleus members.
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR ANNOUNCES EXCLUSIVE COLLABORATION WITH GLOBAL TECHNOLOGY LEADER
Development of a stable liquid formulation for use within partner’s technology
Cambridge, UK, 14 December 2021: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed an exclusive formulation study collaboration.
LONDON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, presented further progress on obecabtagene autoleucel (obe-cel) in an oral presentation [Abstract 477] entitled “Industrialization of an Academic Miltenyi Prodigy-Based CAR T Process” at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, being held between December 11-14, 2021.
AMSBIO has announced a new range of kits, media and reagents to assist in the development of cultured meat products - an exciting new area of food technology.
An independent report has been released today by Stevenage Bioscience Catalyst (SBC) that demonstrates its key role in delivering economic benefit from life sciences research and innovation in the UK.
SBC was formed in 2012 through a collaboration between the Department for Business, Energy and Industrial Strategy (BEIS), GlaxoSmithKline, Wellcome and Innovate UK. Located on the GSK Campus in Stevenage, it is home to the Cell and Gene Therapy Catapult Manufacturing Centre, LifeArc, Cytiva and around 40 thriving start-ups.
Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of Dr Rory Curtis as Vice President US Commercial Operations. The appointment represents the next phase in the Company’s expansion plans and business growth, driven by its ion channel discovery capabilities.
NEW YORK and LONDON, December 7, 2021—ATP (Apple Tree Partners), a leader in life sciences venture capital, today announced the launch of Adendra Therapeutics Ltd. (“Adendra”), a company that will discover and develop treatments for cancers and autoimmune diseases by applying new insights into regulation of adaptive immune responses by dendritic cells.
• Appointment of Dr Gary Clark as Head of Screening Technologies supports Metrion’s cell biology initiative and introduction of new screening platforms
• Service capabilities expanded by addition of 384-well high throughput assay platforms and automated low volume liquid handling systems